Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions
about
NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen SpeciesGene-centric association signals for haemostasis and thrombosis traits identified with the HumanCVD BeadChip.Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.Effects of parecoxib on analgesia benefit and blood loss following open prostatectomy: a multicentre randomized trial.Aspirin and multiple sclerosisHigh-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetesExodontia in dual antiplatelet therapy: the evidence.Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy.Platelet function tests: why they fail to guide personalized antithrombotic medicationNew formulation of old aspirin for better deliveryMarkers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment.Systemic blood coagulation activation in acute coronary syndromes.Evaluation of optical coherence tomography for the measurement of the effects of activators and anticoagulants on the blood coagulation in vitro.Potential roles of cell-derived microparticles in ischemic brain disease.Functional testing methods for the antiplatelet effects of aspirin.The role of antiplatelets in hypertension and diabetes mellitus.Thrombin generation in hemorrhage control and vascular occlusion.A contemporary viewpoint on 'aspirin resistance'.Primary and secondary prevention of cardiovascular disease in diabetes with aspirin.Pharmacology of antiplatelet agents.Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid.Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities.Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events.Anti-platelet agents in pediatric cardiac practice.Changes in platelet function with inflammation in patients undergoing vascular surgery.Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets.Contemporary Use of Oral Antithrombotic Agents: Focus on Dual and Triple Therapeutic Approaches.Optimization and Characterization of Aspirin Encapsulated Nano-liposomes.Clinical Significance of Acute and Serial Platelet Function Testing in Acute Ischemic Stroke.Comparison of protein acetyltransferase action of CRTAase with the prototypes of HAT.Antiplatelet drugs
P2860
Q26784322-AF8941BC-AC80-4658-BD4E-AD28ED8D392BQ33794493-512FC921-2711-42E6-8AA1-BE7A2617CF47Q34433987-CE606FD4-3395-4CCB-A3AC-645E3C287240Q35170196-4D1D3CB2-0F46-47D1-A048-ED9AFC443481Q35678040-CCCFDB9A-3DC5-45EF-9A43-1ED4ED160537Q35688330-5C2D27BB-2AC8-4A47-9873-CE4ACF0BF891Q35953008-8C83D5D6-6BB2-4FC6-844B-2623C625BCC2Q36104404-0C5533F2-7C36-4F4C-BCB4-12196AB8D2CEQ36141482-39A2A9F3-731C-4AB6-AE0A-767CE3C7D4DAQ36373219-6A35BC1A-8D08-4F56-8097-C6D51F907C6EQ36555722-5E68CB90-CF44-4167-B43E-E39BB67A458AQ37116951-446F255A-ECD1-4FCD-AF5C-B65169858239Q37466545-578982C2-609F-477E-966E-3DE26CCA2A2FQ37590447-DF5F8D07-E368-4526-9678-AF246176D6F2Q37841562-98C70460-FA24-4053-A625-2F9C1436F3A6Q37861894-A64005E5-D1DA-455A-A622-4906323A078DQ37900072-A7EAE889-7438-4841-9F10-1381FD9C9648Q37989558-CD730158-75AD-4529-A984-0C3CE96E2184Q38003113-DC1A8359-310E-458E-B169-EFF0948930FBQ38154211-8A523F36-D097-4FC5-AA77-59585A816F25Q38248477-073CC4CD-B6A2-4C78-B2F5-6B04C58FF60AQ38603046-3C5EDC8A-8A14-47BA-8D10-9B0CB5A1C065Q38980493-9F77E4F4-FBF4-41E3-BA70-6D832BB27D14Q40036899-3F9DE901-E76C-4911-B409-9BDB695B6704Q47331979-287C9DE8-3912-422E-B514-BF177BEFDBC6Q48512017-7657671C-55EF-431F-8EA9-62A321795D0AQ48639751-396DA69B-4D2E-4424-B5A2-582894F49ACAQ54980453-C4F32257-2FAD-4A82-8B14-AC5EA95DC01DQ55438892-BF16C23D-EED6-47AF-B7B9-779B1D2B858AQ55452081-4551D7C8-E601-4978-A58A-523CE0837B50Q58481433-929F04AF-196C-471D-B2A7-4C8D839A2D4E
P2860
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Antithrombotic properties of a ...... strictly antiplatelet actions
@ast
Antithrombotic properties of a ...... strictly antiplatelet actions
@en
Antithrombotic properties of a ...... strictly antiplatelet actions
@nl
type
label
Antithrombotic properties of a ...... strictly antiplatelet actions
@ast
Antithrombotic properties of a ...... strictly antiplatelet actions
@en
Antithrombotic properties of a ...... strictly antiplatelet actions
@nl
prefLabel
Antithrombotic properties of a ...... strictly antiplatelet actions
@ast
Antithrombotic properties of a ...... strictly antiplatelet actions
@en
Antithrombotic properties of a ...... strictly antiplatelet actions
@nl
P2860
P1433
P1476
Antithrombotic properties of a ...... strictly antiplatelet actions
@en
P2093
Kathleen E Brummel-Ziedins
Kenneth G Mann
P2860
P304
P356
10.1182/BLOOD-2006-01-010645
P407
P50
P577
2007-03-15T00:00:00Z